GIANT CELL ARTERITIS (GCA)
Clinical trials for GIANT CELL ARTERITIS (GCA) explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS (GCA) trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS (GCA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could tame blood vessel disease and slash steroid dependence
Disease control CompletedThis phase 3 study tests whether secukinumab, given as a shot, can help people with giant cell arteritis (a condition causing inflamed blood vessels) achieve remission faster and with less steroids. About 354 adults aged 50 and older took part. The goal is to see if the drug, com…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug may help giant cell arteritis patients cut steroid use
Disease control CompletedThis study tested a drug called upadacitinib in 429 people with giant cell arteritis, a condition that causes inflamed blood vessels. The goal was to see if adding upadacitinib to a shorter course of steroids could help patients achieve and stay in remission compared to a longer …
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
Which drug better protects GCA Patients' hearts? large study investigates
Knowledge-focused CompletedThis study looked at over 1,600 people with giant cell arteritis (GCA), a condition that causes blood vessel inflammation and raises heart risks. Researchers compared two treatments—tocilizumab and methotrexate—to see which one better prevented heart attacks, strokes, or death. U…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:06 UTC